Evaluation of two commercial kits and two laboratory-developed qPCR assays compared to LAMP for molecular diagnosis of malaria.
Bio-Evolution
Biosynex
LAMP
Malaria
Molecular diagnosis
P. falciparum
Plasmodium
qPCR
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
27 Jun 2022
27 Jun 2022
Historique:
received:
08
04
2022
accepted:
06
06
2022
entrez:
27
6
2022
pubmed:
28
6
2022
medline:
30
6
2022
Statut:
epublish
Résumé
Malaria is an infectious disease considered as one of the biggest causes of mortality in endemic areas. This life-threatening disease needs to be quickly diagnosed and treated. The standard diagnostic tools recommended by the World Health Organization are thick blood smears microscopy and immuno-chromatographic rapid diagnostic tests. However, these methods lack sensitivity especially in cases of low parasitaemia and non-falciparum infections. Therefore, the need for more accurate and reliable diagnostic tools, such as real-time polymerase chain reaction based methods which have proven greater sensitivity particularly in the screening of malaria, is prominent. This study was conducted at the French National Malaria Reference Centre to assess sensitivity and specificity of two commercial malaria qPCR kits and two in-house developed qPCRs compared to LAMP. 183 blood samples received for expertise at the FNMRC were included in this study and were subjected to four different qPCR methods: the Biosynex Ampliquick The main results showed that when compared to LAMP, a test with excellent diagnostic performances, the two in-house developed qPCRs were the most sensitive (sensitivity at 100% for the in-house TaqMan qPCR and 98.1% for the in-house HRM qPCR), followed by the two commercial kits: the Biosynex Ampliquick Overall, these results accentuate the role molecular methods could play in the screening of malaria. This may represent a helpful tool for other laboratories looking to implement molecular diagnosis methods in their routine analysis, which could be essential for the detection and treatment of malaria carriers and even for the eradication of this disease.
Sections du résumé
BACKGROUND
BACKGROUND
Malaria is an infectious disease considered as one of the biggest causes of mortality in endemic areas. This life-threatening disease needs to be quickly diagnosed and treated. The standard diagnostic tools recommended by the World Health Organization are thick blood smears microscopy and immuno-chromatographic rapid diagnostic tests. However, these methods lack sensitivity especially in cases of low parasitaemia and non-falciparum infections. Therefore, the need for more accurate and reliable diagnostic tools, such as real-time polymerase chain reaction based methods which have proven greater sensitivity particularly in the screening of malaria, is prominent. This study was conducted at the French National Malaria Reference Centre to assess sensitivity and specificity of two commercial malaria qPCR kits and two in-house developed qPCRs compared to LAMP.
METHODS
METHODS
183 blood samples received for expertise at the FNMRC were included in this study and were subjected to four different qPCR methods: the Biosynex Ampliquick
RESULTS
RESULTS
The main results showed that when compared to LAMP, a test with excellent diagnostic performances, the two in-house developed qPCRs were the most sensitive (sensitivity at 100% for the in-house TaqMan qPCR and 98.1% for the in-house HRM qPCR), followed by the two commercial kits: the Biosynex Ampliquick
CONCLUSION
CONCLUSIONS
Overall, these results accentuate the role molecular methods could play in the screening of malaria. This may represent a helpful tool for other laboratories looking to implement molecular diagnosis methods in their routine analysis, which could be essential for the detection and treatment of malaria carriers and even for the eradication of this disease.
Identifiants
pubmed: 35761324
doi: 10.1186/s12936-022-04219-1
pii: 10.1186/s12936-022-04219-1
pmc: PMC9238120
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
204Investigateurs
Adela Angoulvant
(A)
Anne Pauline Bellanger
(AP)
Antoine Huguenin
(A)
Anthony Marteau
(A)
Agnes Durand
(A)
Céline Tournus
(C)
Céline Nourrisson
(C)
Céline Malassigne
(C)
Cécile Garnaud
(C)
Caroline Lohmann
(C)
Edith Mazars
(E)
Emilie Sitterle
(E)
Eric Dannaoui
(E)
Françoise Botterel
(F)
Guillaume Desoubeaux
(G)
Ghania Belkadi
(G)
Isabelle Salimbeni
(I)
Jean Philippe Lemoine
(JP)
Luce Landraud
(L)
Louise Basmaciyan
(L)
Loic Favennec
(L)
Marie Fleur Durieux
(MF)
Marie Laure Darde
(ML)
Milene Sasso
(M)
Marc Thellier
(M)
Naima Dahane
(N)
Nathalie Fauchet
(N)
Nathalie Bourgeois
(N)
Odile Eloy
(O)
Odile Fenneteau
(O)
Pascale Penn
(P)
Pauline Caraux Paz
(PC)
Roseanne Lavergne
(R)
René Nabias
(R)
Sorya Belaz
(S)
Sylvain Mermond
(S)
Samia Hamane
(S)
Sébastien Larréché
(S)
Sylvain Clauser
(S)
Stéphane Lastere
(S)
Yaye Senghor
(Y)
Yohann Le Govic
(Y)
Informations de copyright
© 2022. The Author(s).
Références
Malar J. 2019 Jan 15;18(1):9
pubmed: 30646918
Sci Rep. 2015 Oct 28;5:15671
pubmed: 26507008
PLoS Comput Biol. 2010 Sep 16;6(9):
pubmed: 20862303
J Clin Microbiol. 2019 Dec 23;58(1):
pubmed: 31666363
Malar J. 2018 Sep 17;17(1):333
pubmed: 30223852
Sci Rep. 2018 Jan 10;8(1):300
pubmed: 29321578
Am J Trop Med Hyg. 2020 Oct;103(4):1549-1552
pubmed: 32748776
EBioMedicine. 2015 Jul 29;2(9):1186-92
pubmed: 26501116
Malar J. 2014 Feb 24;13:68
pubmed: 24564912
Clin Infect Dis. 2021 Sep 15;73(6):e1387-e1390
pubmed: 33693719
J Infect Dis. 2010 May 15;201(10):1544-50
pubmed: 20380562
Lancet Glob Health. 2017 Oct;5(10):e1038-e1046
pubmed: 28867401
Malar J. 2009 Dec 12;8:293
pubmed: 20003378
Clin Microbiol Rev. 2002 Jan;15(1):66-78
pubmed: 11781267
Nucleic Acids Res. 2000 Jun 15;28(12):E63
pubmed: 10871386
Malar J. 2013 Aug 08;12:277
pubmed: 23927553
Bull World Health Organ. 2020 Aug 01;98(8):558-568F
pubmed: 32773901
Trop Med Infect Dis. 2020 Jun 19;5(2):
pubmed: 32575405
Malar J. 2009 Dec 09;8:284
pubmed: 20003199
Diagnostics (Basel). 2021 Feb 18;11(2):
pubmed: 33670618
Malar J. 2017 May 6;16(1):189
pubmed: 28477621
Emerg Infect Dis. 2021 Feb;27(2):
pubmed: 33496652